These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 22985433)

  • 1. Pyrimethamine decreases levels of SOD1 in leukocytes and cerebrospinal fluid of ALS patients: a phase I pilot study.
    Lange DJ; Andersen PM; Remanan R; Marklund S; Benjamin D
    Amyotroph Lateral Scler Frontotemporal Degener; 2013 Apr; 14(3):199-204. PubMed ID: 22985433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations.
    Lange DJ; Shahbazi M; Silani V; Ludolph AC; Weishaupt JH; Ajroud-Driss S; Fields KG; Remanan R; Appel SH; Morelli C; Doretti A; Maderna L; Messina S; Weiland U; Marklund SL; Andersen PM
    Ann Neurol; 2017 Jun; 81(6):837-848. PubMed ID: 28480639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALS patients with mutations in the SOD1 gene have an unique metabolomic profile in the cerebrospinal fluid compared with ALS patients without mutations.
    Wuolikainen A; Andersen PM; Moritz T; Marklund SL; Antti H
    Mol Genet Metab; 2012 Mar; 105(3):472-8. PubMed ID: 22264771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Misfolded superoxide dismutase-1 in CSF from amyotrophic lateral sclerosis patients.
    Zetterström P; Andersen PM; Brännström T; Marklund SL
    J Neurochem; 2011 Apr; 117(1):91-9. PubMed ID: 21226712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gender difference in levels of Cu/Zn superoxide dismutase (SOD1) in cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Frutiger K; Lukas TJ; Gorrie G; Ajroud-Driss S; Siddique T
    Amyotroph Lateral Scler; 2008 Jun; 9(3):184-7. PubMed ID: 18574763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype.
    Zetterberg H; Jacobsson J; Rosengren L; Blennow K; Andersen PM
    Eur J Neurol; 2007 Dec; 14(12):1329-33. PubMed ID: 17903209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of smoking and LPO in ALS.
    Anand A; Gupta PK; Prabhakar S; Sharma S; Thakur K
    Neurochem Int; 2014 May; 71():47-55. PubMed ID: 24726768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy.
    Winer L; Srinivasan D; Chun S; Lacomis D; Jaffa M; Fagan A; Holtzman DM; Wancewicz E; Bennett CF; Bowser R; Cudkowicz M; Miller TM
    JAMA Neurol; 2013 Feb; 70(2):201-7. PubMed ID: 23147550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for inhibitors of the SOD1 gene promoter: pyrimethamine does not reduce SOD1 levels in cell and animal models.
    Wright PD; Huang M; Weiss A; Matthews J; Wightman N; Glicksman M; Brown RH
    Neurosci Lett; 2010 Oct; 482(3):188-92. PubMed ID: 20638444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trial of Antisense Oligonucleotide Tofersen for
    Miller TM; Cudkowicz ME; Genge A; Shaw PJ; Sobue G; Bucelli RC; Chiò A; Van Damme P; Ludolph AC; Glass JD; Andrews JA; Babu S; Benatar M; McDermott CJ; Cochrane T; Chary S; Chew S; Zhu H; Wu F; Nestorov I; Graham D; Sun P; McNeill M; Fanning L; Ferguson TA; Fradette S;
    N Engl J Med; 2022 Sep; 387(12):1099-1110. PubMed ID: 36129998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant superoxide dismutase-1 indistinguishable from wild-type causes ALS.
    Synofzik M; Ronchi D; Keskin I; Basak AN; Wilhelm C; Gobbi C; Birve A; Biskup S; Zecca C; Fernández-Santiago R; Kaugesaar T; Schöls L; Marklund SL; Andersen PM
    Hum Mol Genet; 2012 Aug; 21(16):3568-74. PubMed ID: 22595972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knocking down metabotropic glutamate receptor 1 improves survival and disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.
    Milanese M; Giribaldi F; Melone M; Bonifacino T; Musante I; Carminati E; Rossi PI; Vergani L; Voci A; Conti F; Puliti A; Bonanno G
    Neurobiol Dis; 2014 Apr; 64():48-59. PubMed ID: 24361555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical library screening identifies a small molecule that downregulates SOD1 transcription for drugs to treat amyotrophic lateral sclerosis.
    Murakami G; Inoue H; Tsukita K; Asai Y; Amagai Y; Aiba K; Shimogawa H; Uesugi M; Nakatsuji N; Takahashi R
    J Biomol Screen; 2011 Apr; 16(4):405-14. PubMed ID: 21364087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: Treatment experience in clinical practice.
    Meyer T; Schumann P; Weydt P; Petri S; Koc Y; Spittel S; Bernsen S; Günther R; Weishaupt JH; Dreger M; Kolzarek F; Kettemann D; Norden J; Boentert M; Vidovic M; Meisel C; Münch C; Maier A; Körtvélyessy P
    Muscle Nerve; 2023 Jun; 67(6):515-521. PubMed ID: 36928619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for
    Miller T; Cudkowicz M; Shaw PJ; Andersen PM; Atassi N; Bucelli RC; Genge A; Glass J; Ladha S; Ludolph AL; Maragakis NJ; McDermott CJ; Pestronk A; Ravits J; Salachas F; Trudell R; Van Damme P; Zinman L; Bennett CF; Lane R; Sandrock A; Runz H; Graham D; Houshyar H; McCampbell A; Nestorov I; Chang I; McNeill M; Fanning L; Fradette S; Ferguson TA
    N Engl J Med; 2020 Jul; 383(2):109-119. PubMed ID: 32640130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidized/misfolded superoxide dismutase-1: the cause of all amyotrophic lateral sclerosis?
    Kabashi E; Valdmanis PN; Dion P; Rouleau GA
    Ann Neurol; 2007 Dec; 62(6):553-9. PubMed ID: 18074357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metal-deficient SOD1 in amyotrophic lateral sclerosis.
    Hilton JB; White AR; Crouch PJ
    J Mol Med (Berl); 2015 May; 93(5):481-7. PubMed ID: 25754173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two approaches to drug discovery in SOD1-mediated ALS.
    Broom WJ; Auwarter KE; Ni J; Russel DE; Yeh LA; Maxwell MM; Glicksman M; Kazantsev AG; Brown RH
    J Biomol Screen; 2006 Oct; 11(7):729-35. PubMed ID: 16928982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Red cell superoxide dismutase activity in sporadic amyotrophic lateral sclerosis.
    Tuncel D; Aydin N; Aribal Kocatürk P; Ozelçi Kavas G; Sarikaya S
    J Clin Neurosci; 2006 Dec; 13(10):991-4. PubMed ID: 17071091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression.
    Tortelli R; Ruggieri M; Cortese R; D'Errico E; Capozzo R; Leo A; Mastrapasqua M; Zoccolella S; Leante R; Livrea P; Logroscino G; Simone IL
    Eur J Neurol; 2012 Dec; 19(12):1561-7. PubMed ID: 22680408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.